Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-24,683
Closed -$1.41M 496
2024
Q3
$1.41M Sell
24,683
-9,000
-27% -$516K 0.03% 233
2024
Q2
$1.76M Sell
33,683
-26,000
-44% -$1.14M 0.05% 210
2024
Q1
$2.43M Buy
59,683
+32,000
+116% +$1.2M 0.07% 147
2023
Q4
$1.02M Sell
27,683
-40,860
-60% -$1.54M 0.03% 266
2023
Q3
$2.62M Sell
68,543
-10,000
-13% -$410K 0.05% 192
2023
Q2
$2.83M Buy
78,543
+8,623
+12% +$294K 0.06% 204
2023
Q1
$2.67M Buy
+69,920
New +$3.28M 0.06% 226
2022
Q4
Sell
-83,937
Closed -$3.32M 141
2022
Q3
$3.32M Sell
83,937
-4,000
-5% -$177K 0.04% 417
2022
Q2
$3.87M Buy
+87,937
New +$3.8M 0.04% 414

Other funds holding HALO

UBS O'Connor's HALO Position: Q4 2024 in Review

UBS O'Connor sold out of Halozyme (HALO) in Q4 2024, closing a stake of 24,683 shares — an estimated $1.41M sold.

UBS O'Connor first reported a position in HALO in Q2 2022 and held it in 9 quarters. The position peaked at $3.87M in Q2 2022. 508 funds tracked by Wall St. Rank hold HALO as of Q4 2024.

  • UBS O'Connor reported no remaining Halozyme position as of Q4 2024 after selling out during the quarter.
  • UBS O'Connor sold 24,683 Halozyme shares in Q4 2024, an estimated $1.41M.
  • UBS O'Connor first reported a position in Halozyme in Q2 2022 and held it in 9 quarters.
  • UBS O'Connor's Halozyme position peaked at $3.87M in Q2 2022.
  • 508 funds tracked by Wall St. Rank held Halozyme as of Q4 2024.

Based on UBS O'Connor's 13F filing for Q4 2024, filed 14 Feb 2025.